UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
2013, T & T Clark library of biblical studies, ISBN 0567177076, Volume 490, vii, 281
Book
2004, ISBN 1570035563, xvii, 299
Book
Journal of medical biography, ISSN 0967-7720, 5/2020, Volume 28, Issue 2, pp. 83 - 89
Journal Article
1935, 208
Book
Book
1935, viii, 253
Book
Journal for the study of the New Testament, ISSN 0142-064X, 9/2010, Volume 33, Issue 1, pp. 59 - 80
Journal Article
Homeland security affairs, 05/2009, Volume 5, Issue 2
Journal Article
1734, Volume no. 3851.
eBook
1994, ISBN 0863329314, 102 p., [16] p. of plates
Book
Human genetics, ISSN 0340-6717, 06/2017, Volume 136, Issue 6, pp. 665 - 677
Journal Article
14.
Full Text
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Neurobiology of disease, ISSN 0969-9961, 2011, Volume 42, Issue 3, pp. 360 - 367
Neurology | Ammonium chloride | Lysosomal inhibition | Exosome | Bafilomycin A1 | Alpha-synuclein | Transmission | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Exosomes - metabolism | Immunohistochemistry | Cell Line | Cell Proliferation | Enzyme-Linked Immunosorbent Assay | Humans | Cells, Cultured | Blotting, Western | Lysosomes - metabolism | Statistics, Nonparametric | Neurons - metabolism | Parkinson Disease - metabolism | alpha-Synuclein - metabolism | Ammonium compounds | Disease transmission | Parkinson's disease | Ammonium paratungstate | Index Medicus
Journal Article
2016, ISBN 9781843844327, x, 285
Book
Journal of hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 5, pp. 1037 - 1046
Gastroenterology and Hepatology | NAFLD | NLR proteins | Inflammasomes | Hepatocytes | Cholesterol crystals | Interleukin-1β | Kupffer cells | Fibrosis | Methionine | NLRP3 | Diet, atherogenic | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Sulfones - therapeutic use | Reactive Oxygen Species - metabolism | NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors | Interleukin-1beta - blood | Non-alcoholic Fatty Liver Disease - drug therapy | Non-alcoholic Fatty Liver Disease - complications | Liver Cirrhosis, Experimental - prevention & control | Hepatitis - prevention & control | Animals | Heterocyclic Compounds, 4 or More Rings - therapeutic use | NF-kappa B - physiology | Female | Mice | NLR Family, Pyrin Domain-Containing 3 Protein - physiology | Disease Models, Animal | Liver | Liver diseases | Animal models | Leukocyte migration | Macrophages | Inflammatory diseases | Caspase-1 | Interleukin 6 | Fatty liver | Atherogenic diet | Myeloid cells | Phenotypes | Nutrient deficiency | Diabetes mellitus | Crystals | Caspase | Leukocytes (neutrophilic) | Inflammation | Cholesterol | Diet | Choline | Liver cirrhosis | Monocyte chemoattractant protein 1 | Index Medicus | atherogenic
Journal Article
2001, Routledge key guides, ISBN 9780415231268, xiv, 254
Book
Nature (London), ISSN 0028-0836, 04/2011, Volume 472, Issue 7341, pp. 32 - 32
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Anti-Bacterial Agents - economics | Leadership | Drug Industry - trends | United States | Drug Discovery - economics | Drug Industry - legislation & jurisprudence | Humans | Drug Discovery - trends | Drug Resistance, Bacterial | Drug Discovery - methods | International Cooperation | Models, Economic | Federal Government | United States Food and Drug Administration - legislation & jurisprudence | Clinical Trials, Phase III as Topic - economics | Drug Industry - economics | Drug Design | Anti-Bacterial Agents - biosynthesis | Drug Discovery - legislation & jurisprudence | Market entry | Incentives | Antibiotics | Investments | Antimicrobial agents | Nosocomial infections | FDA approval | Pharmaceutical industry | Cost control | Biotechnology industry | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 2, pp. 136 - 148
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antifibrinolytic Agents - therapeutic use | Coronary Artery Disease - surgery | Thrombosis - chemically induced | Humans | Middle Aged | Male | Antifibrinolytic Agents - adverse effects | Hemorrhage - prevention & control | Blood Transfusion - statistics & numerical data | Seizures - chemically induced | Heart Valves - surgery | Reoperation - statistics & numerical data | Aged, 80 and over | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Postoperative Complications - chemically induced | Double-Blind Method | Intraoperative Complications - prevention & control | Coronary Artery Disease - mortality | Tranexamic Acid - therapeutic use | Tranexamic Acid - adverse effects | Coronary Artery Bypass | Aged | Hemorrhage - chemically induced | Usage | Care and treatment | Tranexamic acid | Diagnosis | Hemorrhage | Patients | Health aspects | Risk factors | Coronary arteries | Heart | Surgical outcomes | Myocardial infarction | Cerebral infarction | Aspirin | Heart surgery | Coronary artery | Clinical trials | Bleeding | Embolism | Tamponade | Acids | Intestine | Coronary vessels | Surgery | Renal failure | Seizures | Index Medicus | Abridged Index Medicus
Journal Article